Lexicon Pharmaceuticals | LXRX - Equity Capital And Reserves


Lexicon Pharmaceuticals reported $129.44M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Abbott USD 52.13B 1.3B Dec/2025
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Akebia Therapeutics USD 32.61M 8.98M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Illumina USD 2.72B 342M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Ironwood Pharmaceuticals USD -264.16M 44M Sep/2025
J&J USD 78.47B 0 Sep/2025
Lexicon Pharmaceuticals USD 129.44M 6.41M Jun/2025
MacroGenics USD 67M 20.38M Sep/2025
MannKind USD -51.02M 6.47M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 8.65B 680M Dec/2025
Novartis USD 44.75B 2.7B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Thermo Fisher Scientific USD 53.54B 2.38B Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
United Therapeutics USD 7.1B 506M Dec/2025
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025